Literature DB >> 29247996

IL-1 and IL-1 regulatory pathways in cancer progression and therapy.

Alberto Mantovani1,2,3, Isabella Barajon2, Cecilia Garlanda1,2.   

Abstract

Inflammation is an important component of the tumor microenvironment. IL-1 is an inflammatory cytokine which plays a key role in carcinogenesis and tumor progression. IL-1 is subject to regulation by components of the IL-1 and IL-1 receptor (ILR) families. Negative regulators include a decoy receptor (IL-1R2), receptor antagonists (IL-1Ra), IL-1R8, and anti-inflammatory IL-37. IL-1 acts at different levels in tumor initiation and progression, including driving chronic non-resolving inflammation, tumor angiogenesis, activation of the IL-17 pathway, induction of myeloid-derived suppressor cells (MDSC) and macrophage recruitment, invasion and metastasis. Based on initial clinical results, the translation potential of IL-1 targeting deserves extensive analysis.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  inflammation; inflammation-associated cancer; interleukin-1; therapy

Mesh:

Substances:

Year:  2018        PMID: 29247996      PMCID: PMC5922413          DOI: 10.1111/imr.12614

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  51 in total

Review 1.  Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm.

Authors:  Subhra K Biswas; Alberto Mantovani
Journal:  Nat Immunol       Date:  2010-09-20       Impact factor: 25.606

2.  The growing diversity and spectrum of action of myeloid-derived suppressor cells.

Authors:  Alberto Mantovani
Journal:  Eur J Immunol       Date:  2010-12       Impact factor: 5.532

3.  IL-1β regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function.

Authors:  Moshe Elkabets; Vera S G Ribeiro; Charles A Dinarello; Suzanne Ostrand-Rosenberg; James P Di Santo; Ron N Apte; Christian A J Vosshenrich
Journal:  Eur J Immunol       Date:  2010-12       Impact factor: 5.532

Review 4.  The interleukin-1 family: back to the future.

Authors:  Cecilia Garlanda; Charles A Dinarello; Alberto Mantovani
Journal:  Immunity       Date:  2013-12-12       Impact factor: 31.745

Review 5.  The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions.

Authors:  Ron N Apte; Shahar Dotan; Moshe Elkabets; Malka R White; Eli Reich; Yaron Carmi; Xiaping Song; Tatyana Dvozkin; Yakov Krelin; Elena Voronov
Journal:  Cancer Metastasis Rev       Date:  2006-09       Impact factor: 9.264

Review 6.  Microbiota: a key orchestrator of cancer therapy.

Authors:  Soumen Roy; Giorgio Trinchieri
Journal:  Nat Rev Cancer       Date:  2017-03-17       Impact factor: 60.716

Review 7.  Neutralizing tumor-promoting chronic inflammation: a magic bullet?

Authors:  Lisa M Coussens; Laurence Zitvogel; A Karolina Palucka
Journal:  Science       Date:  2013-01-18       Impact factor: 47.728

8.  Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4.

Authors:  F Colotta; F Re; M Muzio; R Bertini; N Polentarutti; M Sironi; J G Giri; S K Dower; J E Sims; A Mantovani
Journal:  Science       Date:  1993-07-23       Impact factor: 47.728

9.  Increased susceptibility to colitis-associated cancer of mice lacking TIR8, an inhibitory member of the interleukin-1 receptor family.

Authors:  Cecilia Garlanda; Federica Riva; Tania Veliz; Nadia Polentarutti; Fabio Pasqualini; Enrico Radaelli; Marina Sironi; Manuela Nebuloni; Elisabetta Omodeo Zorini; Eugenio Scanziani; Alberto Mantovani
Journal:  Cancer Res       Date:  2007-07-01       Impact factor: 12.701

Review 10.  Regulatory Role of IL-1R8 in Immunity and Disease.

Authors:  Martina Molgora; Isabella Barajon; Alberto Mantovani; Cecilia Garlanda
Journal:  Front Immunol       Date:  2016-04-20       Impact factor: 7.561

View more
  122 in total

1.  High expression level of interleukin-1β is correlated with poor prognosis and PD-1 expression in patients with lung adenocarcinoma.

Authors:  X Ding; J Zhang; M Shi; D Liu; L Zhang; R Zhang; B Su; K Ai
Journal:  Clin Transl Oncol       Date:  2020-05-29       Impact factor: 3.405

2.  An Interleukin-1 Signature in Breast Cancer Treated with Interleukin-1 Receptor Blockade: Implications for Treating Cytokine Release Syndrome of Checkpoint Inhibitors.

Authors:  Charles Anthony Dinarello
Journal:  Cancer Res       Date:  2018-09-15       Impact factor: 12.701

3.  IL1α Antagonizes IL1β and Promotes Adaptive Immune Rejection of Malignant Tumors.

Authors:  Tian Tian; Serena Lofftus; Youdong Pan; Claire A Stingley; Sandra L King; Jingxia Zhao; Timothy Y Pan; Rebecca Lock; Jacob W Marglous; Kevin Liu; Hans R Widlund; Robert C Fuhlbrigge; Karen Cichowski; Thomas S Kupper
Journal:  Cancer Immunol Res       Date:  2020-03-11       Impact factor: 11.151

4.  Can we use interleukin-1β blockade for lung cancer treatment?

Authors:  Adrian Gottschlich; Stefan Endres; Sebastian Kobold
Journal:  Transl Lung Cancer Res       Date:  2018-04

5.  Role of IL-17RA in the proliferative priming of hepatocytes in liver regeneration.

Authors:  Danilo Piobbico; Daniela Bartoli; Stefania Pieroni; Antonella De Luca; Marilena Castelli; Luigina Romani; Giuseppe Servillo; Maria Agnese Della-Fazia
Journal:  Cell Cycle       Date:  2018-11-11       Impact factor: 4.534

6.  Lactoferrin deficiency induces a pro-metastatic tumor microenvironment through recruiting myeloid-derived suppressor cells in mice.

Authors:  Lingyu Wei; Xuemei Zhang; Jia Wang; Qiurong Ye; Xiang Zheng; Qiu Peng; Ying Zheng; Peishan Liu; Xiaoyue Zhang; Zhengshuo Li; Can Liu; Qun Yan; Guiyuan Li; Jian Ma
Journal:  Oncogene       Date:  2019-08-28       Impact factor: 9.867

Review 7.  The impact of inflationary cytomegalovirus-specific memory T cells on anti-tumour immune responses in patients with cancer.

Authors:  Xiao-Hua Luo; Qingda Meng; Martin Rao; Zhenjiang Liu; Georgia Paraschoudi; Ernest Dodoo; Markus Maeurer
Journal:  Immunology       Date:  2018-09-10       Impact factor: 7.397

Review 8.  Harnessing innate immunity in cancer therapy.

Authors:  Olivier Demaria; Stéphanie Cornen; Marc Daëron; Yannis Morel; Ruslan Medzhitov; Eric Vivier
Journal:  Nature       Date:  2019-10-02       Impact factor: 49.962

Review 9.  Moving towards personalized treatments of immune-related adverse events.

Authors:  Khashayar Esfahani; Arielle Elkrief; Cassandra Calabrese; Réjean Lapointe; Marie Hudson; Bertrand Routy; Wilson H Miller; Leonard Calabrese
Journal:  Nat Rev Clin Oncol       Date:  2020-04-03       Impact factor: 66.675

Review 10.  Immunoregulatory Roles of Extracellular Vesicles and Associated Therapeutic Applications in Lung Cancer.

Authors:  Zhengrong Yin; Jinshuo Fan; Juanjuan Xu; Feng Wu; Yang Li; Mei Zhou; Tingting Liao; Limin Duan; Sufei Wang; Wei Geng; Yang Jin
Journal:  Front Immunol       Date:  2020-08-28       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.